Paxitab Tablets / Film-coated
Paroxetine
20mg
Tabuk Pharmaceutical Manufacturing Co.
| Pack size | 30's (10's Blister x 3) |
|---|---|
| Dispensing mode | POM |
| Source | SAUDI ARABIA |
| Agent | ALPHAMED CO. (AUH) LTD. |
| Retail Price | 44.50 AED |
Available as:
Indications
Paxitab Tablets / Film-coated is used for:
Depression, Anxiety, Panic disorder, Obsessive-compulsive disorder, Posttraumatic stress disorder, Social anxiety disorder, Premenstrual dysmorphic disorder
Adult Dose
Oral
Depression, Anxiety, Posttraumatic stress disorder
Adult: 20 mg daily, increase gradually, if necessary, by 10-mg increments wkly; max: 50 mg/day.
Obsessive compulsive disorder, Social anxiety disorder
Adult: Initially, 20 mg daily, increase wkly in 10-mg increments. Maintenance: 40-60 mg daily.
Panic disorder with or without agoraphobia
Adult: Initially, 10 mg daily, increase wkly in 10-mg increments according to clinical response. Maintenance: 40-60 mg daily.
Elderly: Initially, 10 mg daily, increase if needed by 10 mg/day at 1 wk intervals; max: 40 mg daily.
Hepatic impairment: Severe: 10 mg daily, increase to a max of 40 mg daily as necessary.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment: Severe: 10 mg daily, increase to a max of 40 mg daily as necessary.
Administration
May be taken with or without food. May be taken w/ meals to minimise GI upset.
Contra Indications
Use with or within 14 days of MAOIs; concurrent use with thioridazine or pimozide.
Precautions
Epilepsy, glaucoma, history of mania, cardiac disease, DM, history of bleeding disorders, on drugs with increased risk of bleeding; renal and hepatic impairment; patients receiving electroconvulsive therapy; achlorhydria or high gastric pH (reduced absorption of oral suspension). Pregnancy and lactation. The risk of suicidal behaviour may be higher in young adults, closely monitor. May impair ability to drive or perform tasks. Avoid abrupt withdrawal.
Lactation
Excreted in breast milk; use caution (AAP states effect on nursing infants is unknown but may be of concern)
Pregnancy-Lactation
Pregnancy
Pregnancy category: D
Teratogenic effects: Epidemiologic studies have shown that infants exposed to paroxetine in the first trimester of pregnancy have an increased risk of congenital malformations, particularly cardiovascular malformations
Use late in the third trimester associated with complications in newborns and may require prolonged hospitalization, respiratory support, and tube feeding
A study of nearly 28,000 women taking SSRIs confirmed 5 previously reported birth defercts associated with paroxetine, including heart defects, anencephaly, and abdominal wall defects (BMJ 2015; 351:h3190)
Persistent pulmonary hypertension of the newborn
Potential risk of persistent pulmonary hypertension of the newborn (PPHN) when used during pregnancy
Initial public health advisory in 2006 was based on a single published study; since then, there have been conflicting findings from new studies, making it unclear whether use of SSRIs during pregnancy can cause PPHN
FDA has reviewed the additional new study results and has concluded that, given the conflicting results from different studies, it is premature to reach any conclusion about a possible link between SSRI use in pregnancy and PPHN
FDA recommendation: FDA advises health care professionals not to alter their current clinical practice of treating depression during pregnancy and to report any adverse events to the FDA MedWatch program
A meta-analysis of 7 observational studies, found exposure to SSRIs in late pregnancy (ie, >20 weeks' gestation) more than doubled the risk of PPHN that could not be explained by other etiologies (eg, congenital malformations, meconium aspiration) (BMJ 2014;348:f6932)
Lactation
Excreted in breast milk; use caution (AAP states effect on nursing infants is unknown but may be of concern)
Interactions
Levels/effects inhibited by cyproheptadine, phenytoin. Levels/effects increased by carbamazepine, cimetidine, CYP2D6 inhibitors (e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, pergolide, quinidine, quinine, ritonavir, ropinirole). Increases levels/effects of atomoxetine, carvedilol, clozapine, CYP2B6 substrates (e.g. bupropion, promethazine, propofol, selegiline, sertraline), CYP2D6 substrates (e.g. amphetamines, selected beta-blockers, dextromethorphan, fluoxetine, lidocaine, mirtazapine, nefazodone, risperidone, ritonavir, thioridazine, TCAs, venlafaxine), duloxetine, galantamine, mexilitine, pimozide, procyclidine, propafenone. Decreases levels/effects of CYP2D6 prodrug substrates (e.g. codeine, hydrocodone, oxycodone, tramadol). Inhibits the metabolism of dextromethorphan, haloperidol, thioridazine. Enhances bradycardic effect of beta-blockers.
Enhances toxic effects of other CNS depressants. Increased risk of serotonin syndrome with amphetamines, SSRIs, meperidine, nefazodone, trazodone, serotonin agonists, sibutramine, sympathomimetics, tramadol, venlafaxine. Increases risk of bleeding with NSAIDs, aspirin, warfarin, or other drugs affecting coagulation. Increases sensitivity to amphetamines. Neurotoxicity with lithium. Additive hyponatraemia with loop diuretics. Mania or hypertension with selegiline.
Potentially Fatal: Fatal reactions with nonselective MAOI.
Adverse Effects
Side effects of Paroxetine :
>10% (Based on 40 mg Dose)
Nausea (15-24%), Insomnia (11-24%), Dry mouth (9-18%), Headache (17%), Asthenia (10-15%), Constipation (10-15%), Diarrhea (9-12%), Dizziness (6-14%), Ejaculation disorder (10-15%), Tremor (4-11%),
1-10% (Based on 40 mg Dose)
Anxiety (5-10%), Blurred vision (5-10%), Decreased appetite (5-10%), Impotence (2-9%), Nervousness (2-5%), Paresthesia (2-5%), Hypomania (0.3 to 2.2%)
Frequency Not Defined (Based on 40 mg Dose)
Hypertension, Tachycardia, Emotional lability, Pruritus, Weight gain, Arthralgia, Tinnitus.Vertigo.Angle clossure glaucoma
Serious
Depression exacerbation, Mania (rare), Serotonin syndrome, Suicidal thoughts (rare), Suicide (rare), Seizure (rare), Toxic epidermal necrolysis, Hyponatremia (rare), Bleeding, abnormal (rare).Acute hepatitis (rare).Stevens-Johnson Syndrome
Mechanism of Action
Paroxetine selectively inhibits the reuptake of serotonin. It has limited direct action at other neurotransmitter sites including muscarinic receptors.
Note
Paxitab 20mg Tablets / Film-coated manufactured by Tabuk Pharmaceutical Manufacturing Co.. Its generic name is Paroxetine. Paxitab is availble in United Arab Emirates.
Farmaco UAE drug index information on Paxitab Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.